Back to top
more

Cyclerion Therapeutics, Inc. (CYCN)

(Delayed Data from NSDQ)

$3.72 USD

3.72
506,270

+0.04 (1.09%)

Updated Jun 18, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (218 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in clinical stage. Cyclerion Therapeutics Inc. is based in Cambridge, United States.

General Information

Cyclerion Therapeutics, Inc.

301 BINNEY STREET

CAMBRIDGE, MA 02142

Phone: 857-327-8778

Fax: NA

Web: http://www.cyclerion.com

Email: ir@cyclerion.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date NA

EPS Information

Current Quarter EPS Consensus Estimate NA
Current Year EPS Consensus Estimate NA
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date NA

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 3.68
52 Week High 8.96
52 Week Low 2.08
Beta 1.86
20 Day Moving Average 2,612,925.25
Target Price Consensus 0.00

CYCN

% Price Change
4 Week 18.85
12 Week 20.78
YTD 21.57
% Price Change Relative to S&P 500
4 Week 18.55
12 Week 15.22
YTD 6.99
Share Information
Shares Outstanding (millions) 40.42
Market Capitalization (millions) 150.37
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 42.11%
vs. Previous Quarter 6.78%
   
Sales Growth
vs. Previous Year -93.89%
vs. Previous Quarter -53.38%
   
Price Ratios
Price/Book 2.62
Price/Cash Flow NA
Price / Sales 111.88
ROE
3/31/21 -113.84
12/31/20 -110.17
9/30/20 -105.55
ROA
3/31/21 -59.79
12/31/20 -60.45
9/30/20 -57.77
Current Ratio
3/31/21 3.30
12/31/20 3.45
9/30/20 4.31
Quick Ratio
3/31/21 3.30
12/31/20 3.45
9/30/20 4.31
Operating Margin
3/31/21 -5,280.73
12/31/20 -3,388.59
9/30/20 -2,322.42
Net Margin
3/31/21 -5,280.73
12/31/20 -3,388.59
9/30/20 -2,322.42
Pre-Tax Margin
3/31/21 -5,280.73
12/31/20 -3,388.59
9/30/20 -2,322.45
Book Value
3/31/21 1.42
12/31/20 1.75
9/30/20 2.22
Inventory Turnover
3/31/21 NA
12/31/20 NA
9/30/20 NA
Debt-to-Equity
3/31/21 0.00
12/31/20 0.00
9/30/20 0.00
Debt to Capital
3/31/21 0.00
12/31/20 0.00
9/30/20 0.00